Subjects receiving any investigational drug concurrently.
Subjects receiving any investigational drug concurrently.
Subject is enrolled (concurrently) in another investigational study, with the exception of the follow-up period of another investigational study in which no anti-cancer therapy is being administered and where only data are being collected;
Patients who are receiving any other investigational agents concurrently; palliative radiation therapy will be allowed as long as the patient meets all other eligibility criteria
Patients who are receiving any other investigational agents concurrently
Patients who are receiving any other investigational agents concurrently
Patients who are concurrently receiving any other investigational agents
Patients who are receiving any other investigational agents concurrently
Subjects may not be enrolled concurrently on other treatment studies
Subjects concurrently receiving any other investigational agents within 2 weeks prior to the first study treatment
Subjects must not be concurrently receiving disease-modifying therapy in another therapeutic investigational study
Treatment with another investigational agent currently or within 21 days prior to enrollment; patients may participate in other non-treatment studies concurrently if it will not interfere with participation in this study
Patients may not be on any other treatments for their cancer aside from those included in the protocol; patients may not undergo another form of treatment concurrently with this study
Patient may not be concurrently enrolled in another investigational drug treatment study
Participation in another investigational trial concurrently or within 30 days
Participation in another investigational study concurrently or use of another investigational drug within 6 months prior to administration of the first study vaccination;
Steroids are not permitted 3 days prior to T cell infusion and concurrently during therapy.
Patients concurrently receiving any other investigational agents
Patient may not be concurrently enrolled in another investigational drug treatment study
Steroids are not permitted 3 days prior to T cell infusion and concurrently during therapy
Enrollment concurrently in another investigational drug study or within 4 weeks of registration
Participation in other investigational studies concurrently if these therapies include a therapeutic intervention
Investigational drug use within 28 days of the first dose of PLX3397 or concurrently
Subjects who are concurrently receiving any other investigational agents
Patients who are receiving any other investigational agents or anticancer therapy concurrently or within 4 weeks (ie 28 days)
concurrently use other anticancer or experimental treatments
Subjects may not be receiving any other study agents concurrently while on this study
Patients may not be receiving any other investigational agents concurrently with study treatment
Steroids are not permitted 3 days prior to T cell infusion and concurrently during therapy
Patients may not be on any other treatments for their cancer aside from those included in the protocol; patients may not undergo another form of treatment concurrently with this study
Concurrently receiving treatment with calcineurin-inhibitor plus sirolimus (either agent alone is acceptable).
Investigational drug use within 28 days of the first dose of PLX3397 or concurrently.
An investigational drug administered for the diagnosis of seminoma given concurrently or within four weeks of the first fraction of proton therapy administration
Patients who are concurrently participating in any other experimental studies that could affect the primary endpoint of this study
Patients may not be on any other treatments for their cancer aside from those included in the protocol; patients may not undergo another form of treatment concurrently with this study
Patients who are receiving any other investigational agents concurrently
Is concurrently enrolled in another therapeutic clinical trial involving ongoing therapy with any investigational or marketed product or placebo.
Concurrently receiving any other concomitant anticancer or experimental drug therapy
Treatment with another investigational agent currently or within 14 days prior to enrollment; patients may participate in other non-treatment studies concurrently if it will not interfere with participation in this study
Use of an investigational agent for pain control concurrently or within the past 30 days
Participation in another investigational trial concurrently or within 30 days
May be concurrently receiving endocrine or HER2 directed therapy
Use of an investigational agent for pain control concurrently or within the past 30 days
Patients may concurrently participate in other therapeutic clinical trials
Receiving any agent concurrently with CLT-008 infusion which inhibits cell division (e.g., methotrexate or hydroxyurea)
Participants may not be concurrently receiving any other study agents
Has been treated with an investigational agent within 30 days or six half-lives of its biologic activity whichever is longer, before the start of study. (Patients may not be concurrently enrolled on another trial or concurrently treated with another investigational agent)
Participation in another investigational drug trial either concurrently or 30 days prior to surgery
